Boston Family Office LLC has purchased 321,000 shares of Ginkgo Bioworks Holdings (DNA:NYE), Inc. valued at around $542,000, according to a recent disclosure with the SEC. Other institutional investors have also made changes to their positions in the company, with JP Morgan and Raymond James increasing their holdings. Ginkgo Bioworks has received mixed ratings from analysts and its shares are currently trading up 3.4%. The company recently reported quarterly earnings that exceeded expectations, with revenue of $98.29 million. The firm has a market capitalization of $2.53 billion and is expected to post a loss of 29 cents per share for the current year.
DNA Stock Growth
Ginkgo Bioworks has been in the news lately due to some research reports. The company received mixed ratings, with one analyst giving it a sell rating, one a hold rating, and three assigning a buy rating. While Raymond James lowered their target price on Ginkgo Bioworks’ shares, according to STA Research, the company still has an average Analyst ratings of “Strong Buy” and a consensus price target of $4.50.
But there’s some good news too! Ginkgo Bioworks’ shares have been growing, trading up 3.4% and opening at $1.22 on Monday. The company’s 50-day simple moving average is $1.33, while the 200-day simple moving average is $1.78. The firm’s market capitalization is $2.53 billion, with a P/E ratio of -0.95 and a beta of 0.88. The stock’s 12-month low is $1.16, and its 12-month high is $4.91.
DNA Stock Analysis & Forecast
According to 6 analysts’ forecasts for Ginkgo Bioworks Holdings, the average target price is expected to be USD 4.50 over the next 12 months, with an average analyst rating of Strong Buy. However, Stock Target Advisor’s analysis is Bearish, based on 2 positive signals and 6 negative signals. Currently, DNA stock price is USD 1.18, which has dropped by -7.09% over the past week, -11.28% over the past month, and -59.31% over the last year.
Business profile
Ginkgo Bioworks Holdings, Inc. is a company that specializes in developing a platform for cell programming along with its subsidiaries. The platform is primarily used to program cells for the production of various products, including therapeutics, food ingredients, and petroleum-derived chemicals. The company’s services are employed in diverse industries, including agriculture, consumer products, pharmaceuticals, specialty chemicals, and food. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
